Despite encouraging clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable difficulty from PBMs. These companies are typically building obstacles to reimbursement, such as steep expense restrictions and approval processes that hinder consumer access. Industry sug… Read More